Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

MSD Acquires EyeBio for US$3B

May 29, 2024

On 29 May 2024, Merck (MSD) announced the acquisition of privately owned opthalmology focussed biotech EyeBio for US$3 billion, including an upfront payment of US$1.3 billion and $US1.7 billion in milestone payments.  The acquisition has been unanimously approved by EyeBio’s board, and is expected to close in Q3/2024. 

EyeBio’s lead candidate, Restoret™ (EYE103), is a tri-specific antibody for diabetic macular oedema (DME) and neovascular age-related macular degeneration and is expected to enter pivotal studies for DME in the second half of 2024.  

In March 2024, MSD completed its acquisition of Harpoon Therapeutics for about US$650M with the aim of augmenting and diversifying its oncology pipeline.